CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT03241940
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:27:39.198752+00:00
- Published At
- 2025-06-29T00:00:00+00:00
- Record Updated At
- 2025-06-29
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["B Acute Lymphoblastic Leukemia", "CD19 Positive", "Minimal Residual Disease", "Philadelphia Chromosome Positive", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Refractory Acute Lymphoblastic Leukemia"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-06-29"- protocolSection.identificationModule.nctId
"NCT03241940"- protocolSection.identificationModule.officialTitle
"Phase I Dose Escalation Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies"- protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.